英夫利西单抗治疗儿童克罗恩病的临床效果  

The clinical effects of infliximab therapy in children with Crohn's disease

作　　者：方莹[1] 任晓侠[1] 韩亚楠[1] 陈一[1] 

机构地区：[1]西安市儿童医院消化内科,西安710043

出　　处：《中国医学前沿杂志（电子版）》2015年第5期67-70,共4页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：目的观察英夫利西单抗治疗儿童克罗恩病的临床效果。方法将本院收治的74例克罗恩病患儿按照入院顺序分为观察组和对照组,每组各37例。对照组患儿采用皮质类固醇激素治疗,观察组患儿采用英夫利西单抗治疗。比较两组患儿临床疗效,治疗后内镜改善情况,治疗前后血清白细胞介素(IL)-2、IL-6、IL-8水平及不良反应发生情况。结果观察组患儿治疗有效率为89.19%(33/37),高于对照组[83.78%(31/37)];观察组患儿内镜改善有效率为91.89%(34/37),优于对照组[86.48%(32/37)],但差异均无显著性(P>0.05)。治疗前两组患儿炎性因子水平比较差异均无显著性(P>0.05),治疗后两组患儿炎性因子水平较治疗前均有所改善,观察组改善效果优于对照组,差异具有显著性(P<0.05)。对照组患儿不良反应发生率为10.81%(4/37),高于观察组[2.70%(1/37)],但差异无显著性(P>0.05)。结论英夫利西单抗治疗儿童克罗恩病效果显著,能有效调节炎性因子水平,提高患儿生活质量,值得临床推广应用。Objective To observe the clinical effects of infliximab therapy in children with Crohn＇s disease. Method The hospital treated 74 cases of children with Crohn＇s disease in accordance with the order of admission were divided into observation group and control group, 37 cases in each group. Control group were treated with corticosteroid hormone therapy, and observation group were taken infliximab therapy. Compared two groups of clinical curative effects, endoscopic improvement after treatment, the levels of serum interleukin（IL）-2, IL-6, IL-8 before and after the treatment and adverse reactions. Result The observation group with the effective rate of treatment was 89.19%（33/37）, higher than control group [83.78%（31/37）], the observation group with endoscopic improvement rate was 91.89%（34/37）, better than control group [86.48%（32/37）], but there were no significant differences（P〉0.05）. Two groups of children with inflammatory factor levels had no significant differences before treatment（P〉0.05）, the two groups compared with before treatment, the levels of inflammatory factors after treatment were improved, the improvement effect of observation group was significantly better than control group, the difference was significant（P〈0.05）. The incidence rate of adverse reactions in the control group was 10.81%（4/37）, higher than observation group [2.70%（1/37）], but the difference had no significant（P〉0.05）. Conclusion Children with Crohn＇s disease taking infliximab treatment, can effectively adjust the level of inflammatory factors, worthy of clinical popularization and application.

关 键 词：英夫利西单抗 激素 克罗恩病 

分 类 号：R725.7[医药卫生—儿科]